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Background: While nitric oxide (NO) signaling is reduced in valves from patients with aortic valve stenosis (AVS), restoring NO signaling 
to slow progression of valve calcification is challenging due to oxidation of soluble guanylate cyclase (sGC), the key target of NO. We 
hypothesized that Ataciguat (ATA), an anthrallic acid derivative that activates oxidized sGC, attenuates osteogenic signaling in valve 
interstitial cells and slows progression of aortic valve calcification.
methods: To determine whether Ataciguat attenuates bone morphogenetic protein signaling in vitro, we treated valve interstitial cells with 
BMP2 (200 ng/ml) or BMP2 + ATA (10 nm) and measured canonical BMP signaling and BMP target gene expression. To determine whether 
Ataciguat slows progression of AVS in mice, 100 ldlr-/-/apoB100/100 mice were assigned to one of two groups:1) 9 months of western diet 
feeding (WD), 2) 9 months of western diet feeding + ATA (5mg/kg ATA). Blood pressure, blood glucose levels, body composition, and aortic 
valve function (cusp separation distance by echocardiography) were measured following 9 months of treatment.
results:   In vitro, treatment of valve interstitial cells with ATA reduced BMP2-dependent Smad1/5/8 phosphorylation and osteogenic gene 
induction by more than 50% (p < 0.01). In vivo, ATA-treated mice did not have significant alterations in blood pressure, blood glucose, or 
body composition compared to mice fed WD. While aortic valve function was not altered in male mice receiving ATA for 9 months (WD = 
0.81±0.02mm, ATA = 0.80±0.02mm). In contrast, aortic valve function was significantly improved in female mice receiving ATA compared to 
the WD group (WD = 0.76±0.02mm, ATA = 0.82±0.02mm; p < 0.05) at the 9 month time point.
conclusion: In conclusion, our data support a working model in which activation of oxidized sGC is a novel therapeutic strategy to slow 
progression of aortic valve calcification and stenosis. Importantly, restoration of sGC signaling does not appear to alter the systemic 
hemodynamic or metabolic milieu, but instead exerts its protective effect through attenuation of local, BMP-dependent osteogenic signaling 
in aortic valve interstitial cells.
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